Business
LSL PHARMA GROUP REPORTS RECORD REVENUES FOR THE SECOND QUARTER 2024
LSL PHARMA GROUP REPORTS RECORD REVENUES FOR THE SECOND QUARTER 2024 Canada NewsWire ...
About this update from Lsl Pharma Group Inc
[{"type":"text","content":"\n\n\n\n LSL PHARMA GROUP REPORTS RECORD REVENUES FOR THE SECOND QUARTER 2024\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n Record Revenues of\n \n $4.2 million\n \n in Q2-24 up 106% over Q2-23\n \n\n Operating profits of\n \n $0.3 million\n \n for Q2-24 compared to a loss of\n \n $0.6 million\n \n for Q2-23\n \n\n Adjusted EBITDA was\n \n $0.7 million\n \n for Q2-24, compared to Adjusted EBITDA loss of\n \n $0.3 million\n \n for Q2- 23\n \n\n Net loss for Q2-24 was\n \n $0.5 million\n \n , down 50% from the\n \n $1.0 million\n \n net loss in Q2-23\n \n\n Completed the acquisition of Virage Santé in\n \n June 2024\n \n\n\n YTD Revenues of\n \n $8.4 million\n \n up 106% over YTD-23\n \n\n YTD Operating Profit of\n \n $0.4 million\n \n compared to an operating loss of\n \n $0.9 million\n \n last year\n \n\n YTD Adjusted EBITDA of\n \n $1.2 million\n \n , up\n \n $1.4 million\n \n over YTD-23\n \n\n YTD Net loss was\n \n $0.8 million\n \n , down 88% from the\n \n $6.4 million\n \n loss for YTD-23\n \n\n Strenghten the balance sheet with financings and debt conversions totalling\n \n $12.7 million\n \n\n\n\n\n\n BOUCHERVILLE, QC\n \n\n ,\n \n\n Aug. 26, 2024\n \n\n /CNW/ -\n \n LSL PHARMA GROUP INC\n \n . (TSXV: LSL) (the \"\n \n Corporation\n \n \" or \"\n \n LSL Pharma\n \n \"), a Canadian integrated pharmaceutical company, today reported its financial and operating results for the three- and six-months periods ended on\n \n June 30, 2024\n \n .\n \n\n\n\n\n\n\n\n\n \"Again during the quarter, LSL Pharma experienced strong demand for our Steri-Med products while our CDMO operations continued to ramp up production following the site relocation, and the implementation of new equipment and services\", commented\n \n Francois Roberge\n \n , President and Chief Executive Officer of LSL Pharma. \"Virage Santé contributed some revenues and margins during the quarter, and we expect to take full advantage of this acquisition over the coming quarters. Following a series of financial transactions aimed at strengthening our balance sheet ...